Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | SQLE | Q14534 | 7/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451127 | 1.00 | KMT2A (0.42) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL18955353 | 0.83 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL18955352 | 0.83 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL18955323 | 0.81 | KMT2A (0.50) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL18955325 | 0.81 | KMT2A (0.50) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3699303 | 0.79 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL3699306 | 0.79 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL7683654 | 0.78 | KMT2A (0.41) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL8700827 | 0.78 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL10509053 | 0.78 | KMT2A (0.73) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | claimed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | claimed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | claimed |
| EP-2825661-B1 | PROCESS FOR PREPARING TERPENE NITRILES FROM TERPENE OXIMES EMPLOYING AN ALDOXIME DEHYDRATASE | BASF SE (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-9080191-B2 | Method for biocatalytic production of nitriles from oximes and oxime dehydratases usable therein | BASF SE (DE) | 2015-07-14 | — | — | US | disclosed |
| EP-2825661-A1 | METHOD FOR PRODUCING TERPENE NITRILES FROM TERPENE OXIMES USING AN ALDOXIME DEHYDRATASE | BASF SE (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-20130244298-A1 | METHOD FOR BIOCATALYTIC PRODUCTION OF NITRILES FROM OXIMES AND OXIME DEHYDRATASES USABLE THEREIN | BASF SE (DE) | 2013-09-19 | — | — | US | disclosed |
| WO-2013135601-A1 | METHOD FOR PRODUCING TERPENE NITRILES FROM TERPENE OXIMES USING AN ALDOXIME DEHYDRATASE | BASF SE (DE) | 2013-09-19 | — | — | WO | disclosed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1390337-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | Givaudan SA (CH) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096850-A1 | PRECURSORS FOR KETONES AND ALDEHYDES | GIVAUDAN SA (CH) | 2002-12-05 | — | — | WO | disclosed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | KMT2A 2984/4885ALOX15 513/4885MAPT 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.